Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes!

Clin Infect Dis. 2020 Oct 23;71(7):1723-1725. doi: 10.1093/cid/ciaa111.

Authors

Sandra A Springer¹, Carlos Del Rio²

Affiliations

¹ Department of Internal Medicine, Division of Infectious Disease, Yale AIDS Program, Yale School of Medicine, New Haven, Connecticut, USA.
² Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.

No abstract available

Keywords: SVR; buprenorphine; hepatitis C virus; medication treatment for opioid use disorder; opioid use disorder.

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Buprenorphine* / therapeutic use
Hepacivirus
Hepatitis C* / drug therapy
Humans
Opioid-Related Disorders* / drug therapy
Pharmaceutical Preparations*

Substances

Pharmaceutical Preparations
Buprenorphine

Grants and funding